Title:The High Potency of Polymeric Nanoparticles in the Drug Delivery System
for Hypertension Treatment: A Systematic Review
Volume: 18
Issue: 1
Author(s): Fatemeh Mohammadipour, Aliasghar Kiani and Arash Amin*
Affiliation:
- Cardiovascular Research
Center, Lorestan University of Medical Sciences, Khorramabad, Iran
Keywords:
Hypertension, blood pressure, polymeric nanoparticles, chitosan, polylactic acid, poly-(lactic-co-glycolic) acid.
Abstract:
Background: Polymeric nanomaterials with sizes ranging from 10 to 1000 nm are one
of the most widely used types of nanoparticles with ideal properties in the drug delivery systems.
Here, we decided to systematically review the antihypertensive effects of polymeric nanomaterials
in vitro, in vivo, and clinical trials.
Methods: The present review was conducted based on the 06- PRISMA guideline; whereas five English
databases, including Scopus, PubMed, Web of Science, EMBASE, and Google Scholar without
time limitation were used for searching the publications related to antihypertensive effects of
natural and synthetic polymeric nanoparticles.
Results: The results demonstrated that among 1701 papers, 25 papers including 11 in vitro (44%),
6 in vivo (24%), 7 in vitro / in vivo (28%), and 1 in vitro / ex vivo (4%) up to 2020, met the inclusion
criteria for discussion in this systematic review. The most used nanoparticles were poly-(lactic-
co-glycolic) acid nanoparticle (PLGANPs) (7, 29.2%), chitosan based nanoparticles (6, 25%),
followed by polylactide acid nanoparticles (5, 20.8%).
Conclusion: We concluded that the high potency of polymeric nanoparticles in the drug delivery
system was for hypertension treatment. Although the accurate mechanisms are not fully understood;
however, some mechanisms, such as sustained release forms with increased bioavailability,
increasing oral bioavailability and improving the oral and non-oral absorption, counteracting excessive
superoxide and decreasing blood pressure, etc. can be related to these nanoparticles.